$10.740
+0.050 (+0.47%)At close
TLX News
TLX Events
Telix Pharmaceuticals Collaborates with Ekalia to Advance US Production of Astatine-211
Telix Pharmaceuticals and Ekalia, a joint venture between Ion Beam Applications and Framatome, announced a collaboration to advance scalable United States production of astatine-211, an alpha-emitting radioisotope being investigated for targeted alpha therapy. The collaboration brings together IBA's specialized alpha-beam cyclotron technology, Framatome's nuclear and isotope production expertise, and Telix's U.S. radiopharmacy and "last-mile" infrastructure, clinical portfolio and radiopharmaceutical development capabilities. The alliance expands into the U.S. the strategic partnership formed by IBA and Framatome in Europe to advance industrial-scale At production. The first installation at RLS Trevose is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops.
Profound Medical Enters Co-Education Agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, as well as the development of educational content, clinical case studies and best-practice materials. The collaboration is intended to increase physician awareness of PSMA-informed treatment pathways, support appropriate patient selection and treatment planning, and expand access to the TULSA Procedure.
Telix Pharmaceuticals Doses First Patients with Pixclara in the U.S.
Telix Pharmaceuticals announced that the first patients in the U.S. have been dosed with Pixclara - floretyrosine F 18 or 18F-FET -, its FDA-approved, amino acid positron emission tomography, or PET, drug for glioma - brain cancer - imaging. The doses were administered at the Indiana University Health Neuroscience Center in Indianapolis and the University Hospitals, Cleveland Medical Center, Cleveland. The milestone marks the start of commercial availability for Pixclara, with Telix's U.S. manufacturing and pharmacy distribution partner, PharmaLogic, supplying finished unit doses to the U.S. market.
Telix Pharmaceuticals Signs Merger Agreement with ITM for $1.65B
Telix Pharmaceuticals announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich, ITM. Under the terms of the agreement and subject to Shareholder approval, Telix will acquire 100% of the shares in ITM for $1.65B upfront on a cash-free/debt-free basis expected as follows: $1.25B will be paid to the sellers in the form of 105.8M Telix shares and released to the sellers as Nasdaq-listed ADRs at the end of their respective escrow periods; $302M of net debt will be assumed by Telix at closing; and $96M of management equity rollover and transaction expenses payable by the sellers; and in each case subject to closing adjustments. Additional contingent consideration of up to US$700 million will become payable upon the achievement of specified regulatory approvals and sales milestones for ITM-11. Upon completion of the transaction, Telix Shareholders will own approximately 76.3% and ITM Shareholders will own approximately 23.7% of Telix shares on issue.
Telix Pharmaceuticals' Pixclara Approved by FDA
Telix Pharmaceuticals announces that the U.S. FDA has approved its New Drug Application for Pixclara, an amino acid positron emission tomography drug for imaging gliomas. Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.